Clinical Trial Enrollment

Liver cancer is one of the most prevalent malignancies in China, with complex management and highly variable prognosis. Lehe stays closely aligned with frontline advances in liver cancer, sourcing clinical trials in targeted therapy, combination immunotherapy, HAIC and TACE, covering subtypes such as advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Our medical team evaluates each patient against liver function, staging and prior therapy, accompanying the journey from screening criteria and enrollment pathway to follow-up management, in order to match the most appropriate protocol and unlock greater treatment opportunities and survival benefit.

Colorectal cancer incidence keeps rising, and subgroups such as MSI-H or KRAS / BRAF mutated patients are in urgent need of individualized precision treatment. Lehe consolidates clinical research projects in immune checkpoint inhibitors, ADCs and novel chemotherapy combinations from both home and abroad, providing enrollment pathways for metastatic disease, post-operative adjuvant therapy and local treatment of oligometastatic lesions. By taking molecular profiling as the entry point, we help even “hard-to-treat” cases receive high-quality diagnosis, treatment and continuous monitoring within a rigorous clinical framework.

Often called the “king of cancers,” pancreatic cancer responds poorly to conventional treatment and urgently needs new breakthroughs. Lehe collaborates deeply with national-level cancer centers, focusing on neoadjuvant therapy, KRAS G12C / G12D targeting, DNA damage repair pathway inhibitors and personalized tumor vaccines, covering resectable, borderline-resectable and advanced patients alike. For every applicant we build a fast and professional bridge to enrollment, so that cutting-edge research can translate into real-world clinical benefit as early as possible, bringing renewed hope back to patients and their families.